ConjuChem

PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing

... Diabetes Patients - MONTREAL, March 26 /CNW/ - conjuchem Biotechnologies Inc. (TSX:CJB) today announced p...d effective in lowering blood glucose levels." conjuchem intends to submit the study results for presentati...7. In conjunction with the multi-dose results, conjuchem also reported that ongoing product development p...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

... MONTREAL, June 19 /CNW/ - conjuchem Biotechnologies (TSX:CJB) today announced that da... a small volume with a small gauge needle. About conjuchem ConjuChem, developer of next generation medicine...ion: Lennie Ryer, CA, Vice President Finance, CFO, conjuchem Biotechnologies Inc., (514) 844-5558 ext 224,

ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4

...AGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - conjuchem Biotechnologies Inc. (TSX:CJB) and Novozymes Bioph...TM):Exendin-4 increases. The Agreement also allows conjuchem to fully assign all rights to a PC-DAC(TM):Exendin-4 licensee. In a separate Agreement, conjuchem and Novozymes Biopharma entered into a Pipeline Pr...

ConjuChem Provides Development Update

...sults - MONTREAL, Nov. 5 /PRNewswire-FirstCall/ - conjuchem Biotechnologies Inc. (TSX:CJB) announced today tha...umin(R), provided by Novozymes Biopharma). About conjuchem Biotechnologies conjuchem Biotechnologies, developer of next generation medi...

Aegera Therapeutics welcomes two experienced executives to its board of directors

...h Capital Management - Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital - Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, conjuchem The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of Aegera's Board Members can be viewed at http://www.aegera.com About Aeger...